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Graft-versus-host disease (GVHD) is a frequent major complication of allogeneic hematopoietic cell trans-
plantation (HCT). Approaches that selectively deplete T cells that cause GVHD from allogeneic stem cell grafts
and preserve T cells speciﬁc for pathogens may improve HCT outcomes. It has been hypothesized that the
majority of T cells that can cause GVHD reside within the naïve T cell (TN) subset, and previous studies per-
formed inmousemodels andwith human cells in vitro support this hypothesis. As a prelude to translating these
ﬁndings to the clinic, we developed and evaluated a novel 2-step clinically compliant procedure for manipu-
lating peripheral blood stem cells (PBSC) to remove TN, preserve CD34þ hematopoietic stem cells, and provide
for aﬁxed dose ofmemory Tcells (TM) that includes Tcellswith speciﬁcity for commonopportunistic pathogens
encountered after HCT. Our studies demonstrate effective and reproducible performance of the immuno-
magnetic cell selection procedure for depleting TN. Moreover, after cell processing, the CD45RA-depleted PBSC
products are enriched for CD4þ and CD8þ TM with a central memory phenotype and contain TM cells that are
capable of proliferating and producing effector cytokines in response to opportunistic pathogens.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION memory (T ) subsets, the latter of which includes effector
Graft-versus-host disease (GVHD) is a frequent cause of
morbidity and mortality after allogeneic hematopoietic cell
transplantation (HCT) because of direct organ damage and
opportunistic infections that result from immunosuppressive
therapies [1]. In human leukocyte antigen (HLA)-identical
HCT, GVHD results from recognition of minor histocompati-
bility (H) antigens expressed on recipient tissues by donor
T cells [1-4]. Prophylactic immunosuppressive drugs are
commonly administered early after HCT to suppress allor-
eactive T cells; however, the incidences of grade II to IV acute
GVHD and extensive chronic GVHD after peripheral blood
stem cell (PBSC) transplantation from HLA-matched sibling
donors remain unacceptably high at 40% to 80% and 40% to
50%, respectively [5-8]. Complete T cell depletion (TCD) of
donor hematopoietic cell products is highly effective for pre-
venting GVHD, but it is complicated by a profound delay in
immune reconstitution, which contributes to life-threatening
infections [9-20]. Thus, the development of approaches that
preferentially deplete from allogeneic stem cell grafts the
T cells that primarily cause GVHD and preserve T cells speciﬁc
for pathogens may improve HCT outcomes.
Mature CD3þCD8þ and CD3þCD4þ T cells can be broadly
classiﬁed into CD45RAþCD62 Lþ naïve (TN) and CD45ROþdgments on page 715.
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memory (TEM) and central memory (TCM) T cells. TN and TM
differ in cell surface phenotype, prior exposure to cognate
antigen, functional activity, and transcriptional programs
[21-27]. It has been hypothesized that the majority of T cells
that can respond to minor H antigens and cause GVHD reside
within the TN subset, unless the donor has developed a TM
response through exposure to allogeneic cells by pregnancy
or blood transfusion [4]. Murine studies, wherein the potency
of TN and TM to induce GVHD have been compared, support
this hypothesis. In mouse models, TN cause severe GVHD,
whereas TCM cause no or mild GVHD and TEM do not cause
GVHD [28-37]. In vitro studies performed with human T cells
have demonstrated that donor CD8þ T cells speciﬁc for
recipient minor H antigens are found predominantly within
the TN subset, suggesting that selective depletion of this
subset may reduce the incidence or severity of GVHD in hu-
manHCT [38]. Here, we describe a clinically compliant process
for effectively engineering human PBSC grafts that are
extensively depleted of CD45RAþ TN but retain both CD34þ
hematopoietic stem cells and functional TM speciﬁc for a broad
range of opportunistic pathogens. This strategy for preparing
PBSC products is currently being evaluated in a clinical trial.MATERIALS AND METHODS
Human Subjects
Cell selection procedures were performed on granulocyte colonye
stimulating factor (GCSF)emobilized peripheral blood stem cell products
(G-PBSC) obtained from an initial cohort of HCT donors participating in a
clinical trial of TN depletion being conducted at Fred Hutchinson CancerTransplantation.
M. Bleakley et al. / Biol Blood Marrow Transplant 20 (2014) 705e716706Research Center (FHCRC) and Yale University School of Medicine under a
Food and Drug Administration investigational device exemption. The insti-
tutional review boards of the FHCRC and Yale University School of Medicine
approved the clinical trial, and the related HCT donors and recipients pro-
vided informed written consent in accordance with the Declaration of
Helsinki. Full details of the trial protocol and clinical outcomes will be
described in a subsequent publication upon completion of enrollment and
data analysis. HCT donors and recipients consented to providing an aliquot
of the starting G-PBSC and CD45RA-depleted G-PBSC products to evaluate
the cellular composition of the graft and the presence of T cell responses to
pathogen-derived antigens. Blood samples and G-PBSC were also obtained
from normal volunteer and HCT donors who participated in research pro-
tocols approved by the institutional review board of FHCRC to develop the
cell selection procedures, and they provided written consent in accordance
with the Declaration of Helsinki.
Cell Processing
A 2-step cell processing procedure that involved selection of CD34þ cells
followed by depletion of CD45RAþ cells was performed on G-PBSC apheresis
products using the CliniMACs instrument (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). CD34þ selections were performed using the CliniMACS
CD34 reagent system (Miltenyi Biotec GmbH) [20,39]. A good manufacturing
practiceegrade murine aCD45RA mAb (clone T6D11) directly conjugated to
Miltenyi iron dextran beads was produced by Miltenyi Biotec under contract
from the NIH Rapid Access to Intervention Development program and used
for depletion of CD45RAþ cells from the CD34- fraction. In brief, processing
involved the following steps: G-PBSC apheresis products were obtained from
donors, sampled, and stored overnight at 4C before processing. If the cell
concentration of the product was greater than 200 106 cells/mL, the volume
was increased by the addition of 1% human serum albumin/Normosol-R to
reduce the cell concentration to 200  106 cells/mL. The total nucleated cell
and CD34þ cell numbers were used to determine whether to proceed to cell
processing immediately after overnight storage or to pool the initial apheresis
product with a second product collected the following day.
CD34þ cell selection
We set a postselection CD34þ cell dose target of> 5.0 106 CD34þ cells/
kg because CD34þ cell doses exceeding this threshold have been associated
with improved overall survival in recipients of PBSC transplantation [40].
After overnight storage or pooling, cells were washed twice with CliniMACS
PBS/EDTA buffer (Miltenyi Biotec GmbH). Cells were then incubated on a
rotator for 30 minutes with CD34-reagent according to manufacturer’s in-
structions. After incubation, cells were washed once and then loaded onto a
CliniMACS Cell Selection instrument (Miltenyi Biotec GmbH). An LS tubing
set was used for the selection regardless of the number of cells loaded
(Miltenyi Biotec GmbH). The CD34 Selection 2 program software version
2.40 was used for selection (Miltenyi Biotec GmbH), and the resulting CD34-
enriched cell population was evaluated for sterility, total nucleated cell
count using a hematology analyzer, and content and viability of CD34þ,
CD3þ, and CD3þCD45RAþCD45RO cells using a FACSCalibur ﬂow cytometer
(BD Biosciences, San Jose, CA).
CD45RAþ cell depletion
We set a target CD3þ T cell dose of 1  107 T cells/kg because this total
number of T cells is 10- to 100-fold greater than the threshold dose of un-
selected T cells predicted to cause GVHD after HLA-identical sibling HCT [41]
and approximates the dose in an unmanipulated bonemarrowallograft, and
would, therefore, be appropriate to test the hypothesis that CD45RA T cells
can be transplanted with less GVHD. We reasoned that this total T cell dose
would also provide a sufﬁcient number of TM cells to improve immune
reconstitution as compared with immune constitution in recipients of a TCD
allograft. We restricted the allowable number of CD3þCD45ROCD45RAþ TN
to < 7.5  104 TN/kg, based on estimates that quantities exceeding this
number would be sufﬁcient to cause GVHD [41]. We utilized a maximum of
41010 total nucleated cells, including nomore than 21010 CD45RAþ cells
from the CD34-depleted fraction for the CD45RA-depletion step (the cell
numbers were limited by the speciﬁcations of the DTS tubing set). The cells
were washed and then incubated on a rotator for 30minutes with 1 bottle of
CD45RA reagent. After incubation, cells were washed once and then loaded
onto the CliniMACS Cell Selection instrument. A DTS tubing set and the
Depletion 3.1 programwas used for the selection, and the CD45RA-depleted
cell populationwas evaluated for sterility, total nucleated cell count, content
of CD34þ, CD3þ, and CD3þCD45RAþCD45RO cells, and viability (Miltenyi
Biotec GmbH).
Multiparametric Flow Cytometric Analysis of Cell Products
Phenotypic characterization of the initial G-PBSC and CD45RA-depleted
G-PBSC cell products was performed using a custom LSR II ﬂow cytometerequipped with 405 nm, 488 nm, 532 nm, and 635 nm lasers (BD Bio-
sciences). Fluorochrome conjugated mAbs to the following molecules were
obtained from BD Biosciences: CD3, CD8, CD4, CD45RO, CD45RA, CD27,
CD28, CD19, CD56, CD16, CD14, CD34, IL2, and IFN-g; antibodies to CD25 and
FoxP3 were from eBioscience (San Diego, CA), CCR7 from R & D Systems
(Minneapolis, MN), and CD28 from Beckman Coulter (Indianapolis, IN).
MHC-tetramer analysis for viral-speciﬁc T cells was performed using iTag
MHC tetramers purchased from Beckman Coulter. G-PBSC were surface
labeled with antibodies or tetramers for 20 or 30 minutes, respectively, at
4C. For T regulatory cell analysis, samples were ﬁxed in ﬁxation per-
meabilization solution before washing and staining with anti-FoxP3 mAb in
1X Permeabilization buffer (e-Bioscience). Dead cell exclusion was per-
formed using either propidium iodide/RNAse staining buffer (BD Bio-
sciences), DAPI (4’6-diamidino-2 phenylindole, Sigma-Aldrich Saint Louis,
MO), or Live/Dead Fixable Violet (Molecular Probes, Eugene, OR). Analysis
was performed using FlowJo software (Treestar, Ashland, OR).ELISpot Assays
Libraries of 15-mer overlapping peptides for the following antigens
were used in ELISpot assays: CMV (pp65 and IE-1), EBV (BZLF1, EBNA1, and
LMP2A), and adenovirus (AdV5 Hexon) (Miltenyi Biotec “PepTivators”).
Before performing ELISpot assays to detect antigen-speciﬁc T cells, we
stimulated aliquots of G-PBSC and CD45RA-depleted G-PBSC once with
peptide-pulsed autologous monocyte-derived dendritic cells (moDC)
generated according to a modiﬁed fast moDC protocol [42]. This approach
improved the feasibility and reliability of the assays in comparison with a
direct ELISpot of the products by circumventing the inhibitory cytokine-
mediated suppressive effects of GCSF-exposed monocytes present in G-
PBSC on IFNg release by T cells, and by expanding antigen-speciﬁc T cells
[43,44]. The ELISpots were performed as described previously [45]. Brieﬂy,
nitrocellulose-bottomed 96-well plates (MultiScreen MAIP N45, Millipore,
Bedford, MA) were coated with an antieIFN-gmAb (clone 1-D1K, Mabtech,
Stockholm, Sweden), and nonspeciﬁc binding was blocked using .5% bovine
serum albumin in RPMI 1640. T cells and peptide-pulsed autologous moDC
were added to the wells and incubated for 18 hours at 37C. T cells stimu-
lated with phytohemagglutinin-pulsed moDC (PHA 10 mg/mL, Sigma-
Aldrich) served as the positive control and T cells exposed to NYBR1 pep-
tide 904 (SLSKILDTV, Genscript) served as the negative control. After
washing, biotinylated IFN-g mAb (clone 7-B6-1, Mabtech), the conjugate
(avidin-peroxidase complex; Vectastain avidin-biotin complex method Elite
kit; Vector Laboratories, Burlingame, CA), and substrate (Vectastain 3-
amino-9-ethylcarbazole substrate) were added according to the manufac-
turer’s instructions. Spot-forming cells were counted by using the Bioreader
5000 optical reader (Bio-sys GMBH, Karben, Germany).Intracellular Cytokine Staining
Antigen-speciﬁc T cells expanded as described above from G-PBSC or
CD45RA-depleted G-PBSC were restimulated for 4 hours at 37C with
peptide-pulsed autologous moDC, unpulsed control autologous moDC, or
autologous lymphoblastoid cell lines in the presence of CD28 and CD49a
costimulatory mAbs (5 mL/mL) (BD Biosciences). Brefeldin A (1 mL/mL
Goligplug, BD Biosciences) was added 1.5 hours into the stimulation. The
cells were then ﬁxed and permeabilized (Cytoﬁx/Cytoperm, BD Biosciences)
and stained with IFN-g, IL2, CD4, and CD8 ﬂuorescenteconjugated mAb (BD
Biosciences) in perm wash buffer (BD Biosciences) before washing and data
collection on a ﬂow cytometer.Lymphoproliferation Assays
CD4þ T cells were enriched from unmanipulated G-PBSC and CD45RA-
depleted G-PBSC by immunomagnetic depletion of other cell subsets
(CD4þ T cell isolation kit, Miltenyi Biotec), and plated at 25,000 cells per well
in replicate wells (4 replicates) of 96-well plates with viral antigen prep-
arations (Microbix Biosystems, Ontario, Canada) including 25 mg/mL of
cytomegalovirus (CMV, Ad-169), adenovirus (AdV), herpes simplex virus 1
(HSV), varicella zoster (VZV), inﬂuenza A (Flu A), and dengue virus (negative
control) or PHA (10 mg/mL Sigma-Aldrich, positive control), and irradiated
PBSC (2500 cells/well) to provide antigen-presenting cells. The cells were
cultured for 6 days with antigen or controls and then pulsed with 1 mCi of 3H
thymidine during the ﬁnal 20 hours of the assay before harvesting and
scintillation counting (Perkin Elmer, Waltham, MA).Statistical Analysis
Statistical analysis was conducted using Prism Software (GraphPad, La
Jolla, CA). Student t-test was conducted as a 2-tailed paired test with a
conﬁdence interval of 95% and results with a P value < .05 were considered
signiﬁcant.
Figure 1. Flow cytometric analysis of normal donor blood cells. Blood cells obtained from normal donors were analyzed by ﬂow cytometry to assist in designing of a
cell selection strategy to deplete TN from G-PBSC. (A) Stability of CD62L and CD45RA expression on CD4þ or CD8þ T cells in G-PBSC at 2 and 24 hours after apheresis
collection (live CD3þ lymphocyte gate). (B) Expression of CD45RA and CD45RO on CD3þ, CD4þ, and CD8þ T cells in normal donors with the typical (panels 1 and 2)
and variant patterns of CD45 expression (panels 3 and 4). Data is shown after gating on live lymphocytes. (C) CD45RA is expressed on a minor subset of CD34þ cells in
samples of normal donor PBMC, or CD34þ cells isolated by positive immunomagnetic selection from G-PBSC.
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Design of a Cell Selection Strategy Using anti-CD45RA to
Deplete TN Cells from G-PBSC
Human TN uniformly express the high molecular weight
CD45RA isoform of the hematopoietic cellespeciﬁc tyrosine
phosphatase CD45 and express several other cell surface
markers, including CD62L, CCR7, CD27, and CD28 [22-25,27].
We considered using anti-CD62L mAb to deplete TN,
consistent with the approach taken in the original murine
studies that demonstrated that donor TN were the most
potent subset for causing GVHD [28]. However, CD62L is
subject to proteolytic cleavage by ADAM-17 and other met-
alloproteases released during G-CSF mobilization of PBSC
[46], and we found that cell surface CD62L expression sub-
stantially declined on T cells in G-PBSC products stored over
24 hours (Figure 1A). Moreover, CD62L is also expressed on
TCM and using this marker for depletion would remove a
potentially critical subset for robust immune reconstitution
[24,47,48]. In contrast, CD45RAwas not subject to proteolytic
cleavage in G-PBSC (Figure 1A) and is absent on most
memory T cells, including TCM. The CD45RAþ ‘TEMRA’ subset
of TM will be removed by CD45RA depletion, but it would be
anticipated that donor TCM transferred in the CD45RA-
depleted PBSC will repopulate the TEMRA subset, based on
recent studies demonstrating that T cell differentiation fol-
lows a linear pathway in which TCM giving rise to TEM and to
effector T (TE) cell subsets [48,49].
Further analysis of CD45RA as a target to deplete TN from
G-PBSC revealed some limitations. First, polymorphisms in
the CD45 gene have been described [50], and 1 variant (allelefrequency 0 to 3.5%) is a C77G point mutation in a splice
silencer region in exon 4 that prevents excision of the exon,
resulting in retentionof CD45RAexpression onmemory Tcells.
To estimate the frequency of aberrant CD45 expression in our
community, we ﬁrst evaluated expression of CD45RA and
CD45RO on T cells in 50 normal donors by ﬂow cytometry and
identiﬁed a phenotype consistent with the C77G variant in 2
donors (4%) (Figure 1B). This result indicated it would be
desirable to screenHCTdonors for this variant and exclude this
minor subset of donors from future clinical trials, as CD45RAþ
depletion would remove all T cells from PBSC products from
such individuals. Second, there are reports that aminor subset
of CD34þ stem cells expresses CD45RA and that the
CD45RAþCD34þ subset is enriched for granulocyte macro-
phageeand megakaryocyte-colony forming units relative to
CD45RACD34þ cells [51]. Staining aliquots of G-PBSC with
both mAb conﬁrmed that a signiﬁcant subset of CD34þ cells
coexpressed CD45RA (Figure 1C). Thus, to preserve all subsets
of CD34þ stem cells in the graft, it was necessary to develop a
2-step immunomagnetic selection procedure involving a
positive selection of CD34þ progenitor cells using anti-CD34
mAb conjugated beads followed by depletion of CD45RAþ
cells from the CD34-negative fraction (Figure 2).
Evaluation of Sequential Positive and Negative Selection
for Preparing G-PBSC Depleted of Naïve T cells
We processed G-PBSC from 15 consecutive normal stem
cell donors using the 2-step selection method. For 10 donors,
sufﬁcient CD34þ cells were obtained from a single apheresis
collection to proceed directly with cell selection, and for 5
Figure 2. Cell selection procedure. The ﬂow diagram depicts the cell pro-
cessing procedure to deplete TN from G-PBSC, preserve CD34þ stem cells and
deliver a ﬁxed dose of TM cells.
M. Bleakley et al. / Biol Blood Marrow Transplant 20 (2014) 705e716708donors, the cell selections were performed after pooling 2
apheresis samples collected on consecutive days. The CD34
selection provided products with a median purity of 97.6%
(range, 92.5% to 98.7%). CD34þ cells provided a yield of 73%
(range, 60% to 81%) and a residual median CD3þ T cell con-
tent of .26% (range, .09% to 1.3%). These purities and yields
are comparable to the values previously reported for CD34þ
selection using the CliniMACS CD34 reagent system [39].
CD45RA depletion was then performed on the CD34-
depleted product and consistently resulted in near complete
depletion of CD45RAþ T cells (Figure 3A,B). An aliquot of
cells from the CD45RA-depleted products of each of the 15
donors could be removed (representing a median of 26% of
the available cells; range, 10% to 65%) to achieve our target
doses of 1 107 CD3þ cells/kg and< 7.5  104 TN cells/kg. The
median residual TN cell content of the CD45RA-depleted
aliquot that contained 1  107 TM/kg was .12  104/kg
(range, .02 to .65104/kg). The 15 donor G-PBSC products that
were processed by sequential CD34 selection and CD45RA
depletionwere composed of a median of 8.47 106/kg CD34þ
cells/kg (range, 5.29 to 14.33 CD34þ/kg), .36  104 TN/kg
(range, .09 to .78  104 TN/kg), and 9.99  106 TM/kg (range,
9.94 to 10.03  106 TM/kg) (Figure 3C,D). The residual TN cells
in the cell product were approximately evenly distributed
between the CD34þ cell component and the CD45RA-depleted
component (Figure 3E). The viability of the cell products was
consistently high at the end of cell processing for both the
CD34þ-enriched and CD45RA-depleted components (CD34þ
median, 98.4%; range, 96.2% to 99.3%; CD45RA-depleted me-
dian, 97.7%; range, 96.3% to 98.8%), and all products met ste-
rility release criteria.Cellular Composition of CD45RA-depleted G-PBSC
The 2-step cell selection was highly effective in removing
CD3þCD45RAþCD45RO TN from G-PBSC. However, CD45RA
is expressed on other hematopoietic cells, including most
B cells, natural killer cells, and a subpopulation of regulatory
T cells (Tregs) [52]. We therefore analyzed the cell composit-
ion of G-PBSCs, before cell selection, and of an aliquot of
CD45RA-depleted G-PBSC prepared for infusion. In addition
to the profound reduction (4.5 to 5 log10) in TN cells, we
observed a 4.5 to 5.0 log10 reduction in CD45RAþ Tregs(CD45RAþCD4þCD3þCD25þFOXP3þ) and total B cells and a 3.4
log10 reduction in total natural killer cells (Table 1). Also
observed was a 1 to 2 log10 reduction in total nucleated cells,
monocytes, total CD3þTcells, CD4þCD3þ andCD8þCD3þTcells,
and CD4þCD3þCD25þFOXP3þ Tregs compared with the com-
position of the unselected product, partially as a consequence
of limiting the T cell content to 1  107 TM cells/kg in the
selected product. There was minimal variation in the compo-
sition of the 15 cell products after the selection procedure
(Figure 4). The TM cells in the CD45RA-depleted product
comprised approximately 80% CD4þ (range, 65% to 93%)
and 20% CD8þ T cells (range, 6% to 32%). The frequency of
CD8þ T cells in the CD45RA-depleted product that expressed a
CD3þCD8þCD45ROþCD45RACCR7þCD27þCD28þ TCM pheno
type was 32.7% (range, 21.3% to 68.7%) compared with 4.03%
(range, 1% to 14.3%) in unmanipulated G-PBSCs. The frequency
of CD4þ T cells in the ﬁnal product that expressed a
CD3þCD4þCD45ROþCD45RACCR7þCD27þCD28þ TCM pheno
type was 68.4% (range, 49.5% to 84.2%) compared with 20.5%
(range, 9.3% to 39.4%) in the unmanipulated G-PBSC.Functional Pathogen-speciﬁc T Cells Are Retained in
CD45RA-depleted G-PBSC
A theoretical advantage of CD45RA-depleted PBSC over
complete TCD as a strategy for HCT is that pathogen-speciﬁc
TM cells should be retained in the graft and could transfer
protective immunity to opportunistic infections such as CMV
and EBV. We used MHC tetramer analysis to enumerate
T cells speciﬁc for immunodominant epitopes from CMV
(pp65, NLVPMVATV [NLV]) and EBV (BMLF1, GLCTLVAML
[GLC]) in G-PBSC and CD45RA-depleted PBSC from a subset
of donors who expressed the HLA-A*0201 restricting allele
and were seropositive for CMV and EBV. EBV GLC-speciﬁc
T cells were present in a similar proportion of the CD8þ
T cell population in PBSC and CD45RA-depleted PBSC.
Although CMV NLV-speciﬁc T cells were observed in lower
frequencies in the CD45RA-depleted PBSC, this population
included a higher proportion of virus-speciﬁc T cells that
expressed CD28 and CCR7 consistent with a TCM phenotype,
implying an enhanced capacity to persist and expand in vivo
(Figure 5). T cells speciﬁc for most other viral antigens are
present at low levels in peripheral blood and PBSC, and
direct analysis is not feasible. Moreover, direct functional
analysis of antigen-speciﬁc T cells in G-PBSC is impaired
because of the cytokine-mediated suppressive effects of
GCSF-exposed monocytes [43,44]. To overcome these ob-
stacles, we measured opportunistic virus-speciﬁc T cell re-
sponses in G-PBSC and CD45RA-depleted G-PBSC after
short-term in vitro T cell expansion. Aliquots of G-PBSC
and CD45RA-depleted G-PBSC were stimulated with autol-
ogous moDC pulsed with pools of 15 mer peptides, spanning
the products of genes that are known to encode immuno-
dominant epitopes from CMV (pp65 and IE-1), EBV (BZLF1,
EBNA1, and LMP2A), and adenovirus (AdV5 Hexon), and then
assayed on day 10 after stimulation by interferon gamma
(IFNg) ELISpot. T cell responses to CMV (CMVpp65 and/or IE-
1) were observed in both the CD45RA-depleted and unma-
nipulated G-PBSC obtained from each of the 5 CMV-positive
donors, but not the 2 CMV-seronegative donors, conﬁrming
that the assay detected memory T cell responses. T cells that
produced IFNg speciﬁcally in response to restimulation with
adenovirus and EBV antigens (BZLF, EBNA1, or LMP2A) were
also present the CD45RA-depleted G-PBSC whenever they
were detected in unmanipulated G-PBSC (Figure 6 A-C),
Figure 3. Results of cell selection procedures. (A) TN (CD45RAþCD45ROCD3þ) content of (CD34-depleted) G-PBSC product, CD45RA-depleted fraction, and CD45RAþ
fraction from cell selection on G-PBSC from a representative donor (gated on live CD3þ T cells). (B) CD3þ TN content in the initial G-PBSC and in an aliquot prepared for
infusion after depletion of CD45RAþ cells on 15 representative donors after adjusting the CD3þ TM content in the CD45RA fraction to 107 cells/kg. (C) Total CD34þ
cell content and (D) CD3þ and TN CD3þCD45RAþ content of the infused cell products. (E) TN (CD3þCD45RAþ) content in the CD34þ fraction and in the CD34- and
CD45RA-depleted cell fraction.
Table 1
Composition of CD45RA-depleted G-PBSC
Cell Subset Starting G-PBSC
(Cells  106/kg)
(Median, Range)
CD45RA-depleted
G-PBSC
(Cells  106/kg)
(Median, Range)
Log Depletion
Total nucleated cells 1369 (1031-1926) 80.85 (43-171) 1.23
CD3þ T cells 382 (257-725) 9.99 (9.94-10.03) 1.58
CD3þTN cells 186 (86.5-570) .0036 (.0009-.0078) 4.71
CD3þTM cells 160.4 (75.7-274) 9.99 (9.94-10.03) 1.20
CD3þCD8þ T cells 174 (95.5-854) 1.62 (.55-3.18) 2.03
CD3þCD4þ T cells 170 (145-369) 8.11 (6.5-9.38) 1.32
CD3þCD8þ TCM cells (CCR7þCD27þCD28þ) 5.64 (1.43-9.84) .55 (.266-.89) 1.01
CD3þCD4þ TCM cells (CCR7þCD27þCD28þ) 41.7 (13.5-96.3) 4.98 (4.00-7.58) .92
CD3þCD4þ CD25þFOXP3þTregs 7.88 (2.69-1.63) .337 (.142-.486) 1.37
CD3þCD4þ CD25þFOXP3þCD45RAþTregs 1.68 (.319-4.32) <.0001 >4
CD3CD56þNK cells 24.5 (12.3-74.6) .009 (.0004-.0462) 3.43
CD19þ B cells 124 (52.9-244) .00164 (.0001-.004) 4.88
CD14þ monocytes 390 (207-714) 23.9 (4.2-63.4) 1.21
G-PBSC indicates granulocyte colonyestimulating factor mobilized peripheral blood stem cell; TN, naïve T cells; TM, memory T cells; TCM, central memory T cells;
NK, natural killer; Tregs, regulatory T cells.
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Figure 4. Cell composition of G-PBSC before and after CD45RA depletion. Enumeration of cell content of G-PBSC before (circles) and after (squares) CD45RA
depletion. (A) Total nucleated cells. (B) CD14þ monocytes. (C) CD3þ CD4þ T cells. (D) CD3þ CD8þ T cells. (E) CD4þ TCM (CD3þCD4þCD45ROþCD45RACCR7þ CD27þ
CD28þ). (F) CD8þ TCM (CD3þCD8þCD45ROþ CD45RACCR7þ CD27þCD28þ). (G) T regulatory cells (CD3þ CD4þ CD25þ FOXP3þCD45RAþ/). (H) CD45RAþ T regulatory
cells (CD3þCD4þCD25þFOXP3þCD45RAþ). (I) CD56þCD3 NK cells. (J) CD19þ B cells. *P < .05 (Student paired t test)
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Figure 5. Virus-speciﬁc T cells in G-PBSC before and after CD45RA depletion. (A) Flow cytometry plots showing MHC tetramer staining for viral epitopes (CMV pp65
NLVPMVATV and EBV BMLF1 GLCTLVAML) of CD8þ T cells enriched from G-PBSC and CD45RA-depleted PBSC from a representative HLA-A2þ CMVþ EBVþ donor. (B)
Tetramer evaluation of G-PBSC and CD45RA-depleted PBSC from 7 HLA-A2þ CMVþ EBVþ donors. (i) CMV NLVespeciﬁc T cells and (ii) EBV GLCespeciﬁc T cells as a
proportion of CD8þ T cells; CD28 expression on (iii) CMV NLV CD8þ and (iv) EBV GLC CD8þ T cells; CCR7 expression on (v) CMV NLV CD8þ and (vi) EBV GLC CD8þ
T cells. Analyzed by Student paired t-test.
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ogens after CD45RA depletion.
The ELISpot assays only measured IFNg production and
did not distinguish responses of CD4þ and CD8þ T cell sub-
sets. The recovery of multifunctional CD4þ and CD8þ virus-
speciﬁc T cells, deﬁned as those capable of producing both
IFNg and IL2, has been associated with superior protection inHCT recipients [53,54]. Therefore, we evaluated IFNg and IL2
secretion by virus-speciﬁc CD4þ and CD8þ T cells expanded
from G-PBSC and from CD45RA-depleted G-PBSC using 15
mer peptide pools for EBNA-1 and pp65. We detected an
equivalent or higher frequency of multifunctional virus-
speciﬁc CD4þ and CD8þ T cells in CD45RA-depleted prod-
ucts, consistent with the removal of CD45RAþ naïve T cells
Figure 6. ELISpot assays evaluating pathogen-speciﬁc IFNg secretion by T cells after peptide stimulation of G-PBSC and CD45RAþ-depleted G-PBSC. (A) Represen-
tative IFN-g ELISpot showing response of T cells from G-PBSC and CD45RA-depleted G-PBSC to pp65 and control (NYBR1) peptides. The ﬁgure shows 1 of 3 replicate
wells for each cell concentration for each condition. (B) IFN-g ELISpot assay of T cells derived from G-PBSC and CD45RAþ-depleted G-PBSC from a CMVþ donor (i) and
a CMV donor (ii) to CMV pp65, CMV IE1, EBV BZLF, EBV EBNA1, EBV LMP2A, or adenovirus 15 mer peptide pools. Shown are the mean and standard deviation of the
spot frequency in response to the viral or control peptide stimulation (PBSC þ viral peptide ¼ black; PBSC þ control ¼ dark grey; CD45RA-depleted PBSC þ viral
peptide ¼ white; CD45RA-depleted þ control ¼ light grey). (C) IFN-g response in donor PBSC (circles) and corresponding CD45RA-depleted PBSC (triangles): re-
sponses to CMV pp65 (i) and IE-1 (ii) peptides in CMV-seropositive donors (upper 5) and CMV-seronegative donors (lower 2), adenovirus (iii), EBV BZLF (iv), EBNA-1
(v), and LMP2A (vi). Responses to control peptide are subtracted from the virus-speciﬁc response. Spot frequencies of < 100/100,000 (<.1%) are considered negative.
Analyzed by Student paired t-test.
M. Bleakley et al. / Biol Blood Marrow Transplant 20 (2014) 705e716712that would be unresponsive in the assay and elimination of
the subset of CD45RAþ effector memory T cells that are less
commonly multifunctional (Figure 7A-C) [55].
Whole protein antigens that are processed through the
MHC class II antigen processing pathway for presentation to
CD4þ T cells are available for more pathogens and encompass
a larger number of potential epitopes than peptide pools. We
used protein antigen preparations for several viruses that can
cause serious infection in HCT recipients, speciﬁcally CMV,
AdV, HSV, VZV, and Flu A in lymphoproliferative assays to
evaluate the retention of virus-speciﬁc CD4þ T cells in
CD45RA-depleted PBSC. In these experiments, CD4þ T cells
were ﬁrst enriched from unmanipulated G-PBSC and
CD45RA-depleted G-PBSC by immunomagnetic depletion of
other hematopoietic cell subsets and plated in 96-well plates
with media alone, dengue viruseantigen preparation (nega-
tive control), PHA (positive control), or with each of the HCT-
virus antigen preparations. All 4 CMV-seropositive donors but
not the 2 CMV-seronegative donors showed a signiﬁcant
CD4þ proliferative response to CMV antigen in both the un-
manipulated G-PBSC and CD45RA-depleted G-PBSC. Strong
speciﬁc CD4þ proliferative responses were also observed
against AdV, HSV, VZV, and Flu A in the unmanipulated G-
PBSC and CD45RA-depleted G-PBSC (Figure 8). Thus, prepar-
ing a G-PBSC product that is depleted of CD45RAþ TN and
contains a ﬁxed dose of 1  107 TM cells/kg preserves multi-
functional CD4þ and CD8þ T cells capable of speciﬁcally
responding to viral antigens.
DISCUSSION
Evidence from animal models demonstrates that the
diverse TN subset has the greatest potential to cause GVHD
after allogeneic HCT [28-37]. Prior studies in our lab have
also shown that puriﬁed CD8þ TN from HLA-identical siblingdonors mediate markedly greater reactivity for disparate
minor H antigens in limiting dilution cultures than puriﬁed
CD8þ TM, suggesting that the in vivo murine model data
may apply to humans [38]. As a prelude to translating the
insights derived from the murine model to the clinic, we
developed a novel 2-step clinically compliant procedure for
manipulating G-PBSC to remove TN, preserve CD34þ he-
matopoietic stem cells, and provide for a ﬁxed dose of
TM cells that includes T cells with speciﬁcity for common
opportunistic pathogens encountered after HCT. Our studies
of 15 consecutive G-GSCFemobilized PBSC products
demonstrate reproducible performance of an immuno-
magnetic cell selection procedure that ﬁrst positively selects
CD34þ cells and then depletes CD45RAþ TN from the CD34
negative fraction. The rationale for ﬁrst positively selecting
CD34þ cells was based on our desire to preserve the subset
of CD34þ cells that express CD45RA and prior data
demonstrating that puriﬁed CD34þ cells selected on the
Miltenyi CliniMACS have high engraftment potential
[20,51,56]. Consistent with previous experience, the positive
selection of CD34þ progenitor cells resulted in a cell product
of high purity, reasonable yield, and a very low residual
T cell content [39]. In the second step, CD45RAþ TN were
effectively depleted from the CD34-depleted fraction using
a newly developed clinical grade aCD45RA immuno-
magnetic bead. Both CD34þ and CD45RA-depleted products
retained high viability during cell processing, and the
resulting cell products consistently met the target cell doses
of > 5  106 CD34þ cells/kg, 1  107 TM/kg, and < 7.5  104
TN/kg. This efﬁcient and reliable method for depleting TN
enables clinical evaluation of the outcome of HLA-matched
allogeneic HCT using donor PBSC grafts that contain
CD34þ stem cells, a ﬁxed number of TM cells, and minimal
contaminating TN cells.
Figure 7. Intracellular cytokine ﬂow cytometry to evaluate virus-speciﬁc T cells derived from PBSC and CD45RA-depleted PBSC. (A) IFNg and IL2 secretion by CD4þ or
CD8þ T cells expanded from G-PBSC or CD45RAþ-depleted G-PBSC after restimulation with EBNA1 peptide or moDC alone. (B&C) Frequency of CD4þ and CD8þ T cells
from G-PBSC or CD45RA-depleted G-PBSC from representative donors that produce IFNg or both IFNg and IL-2 after restimulation with (B) EBNA-1 and (C) pp65
peptides. The frequency of T cells responding to the negative control is subtracted from the data shown in (B) and (C).
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Figure 8. Lymphoproliferation assays to evaluate CD4þ T cell responses to opportunistic pathogens. (A) Proliferation of CD4þ T cells enriched from G-PBSC (striped)
and CD45RAþ-depleted G-PBSC (white) from representative CMVþ (left) and CMV (right) donors after stimulation with protein antigen preparations from dengue
(negative control), CMV, adenovirus, HSV, VZV, and inﬂuenza A viruses. Shown are the mean and standard deviation. (B) Proliferation of CD4-enriched PBSC (circles)
and CD45RA-depleted CD4-enriched PBSC (squares) in response to antigen stimulation with (i) CMV, (ii) ADV, (iii) HSV, (iv) VZV, and (v) inﬂuenza. The stimulation
index shows proliferation relative to negative control wells. A simulation index < 3 is considered negative. Analyzed by Student paired t-test.
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selectively depleted of TN compared with complete TCD is
the potential to retain functional donor TM speciﬁc for
opportunistic pathogens that can confer protection against
infection. Our data show that both CD4þ and CD8þ TM cells
are contained within the CD45RA-depleted G-PBSC product,
and each of these subsets are enriched for cells with a TCM
phenotype. TCM cells have high replicative potential and can
both self renew and differentiate to TEM and TE cell subsets
in vivo [21,24,47,48]. The CD34 selection and CD45RA-
depletion procedures do not interfere with function of the
remaining TM cells. Our data demonstrate that after cell
processing, the TM cells are capable of proliferating and
producing effector cytokines in response to common
opportunistic viruses including CMV, EBV, AdV, HSV, and
VZV. Consistent with the preponderance of T cells with a TCM
phenotype, multifunctional CD4þ and CD8þ T cells that
secreted IL2 and IFNg in response to viral antigen were
prevalent in the CD45RA-depleted G-PBSC. Thus, it is pre-
dicted that recovery of T cell numbers and pathogen-speciﬁc
immunity would be improved in the early post-HCT period
with a CD45RA-depleted graft compared with a graft
completely depleted of T cells [24,47].
A disadvantage of the TN depletion approach is that it
would not remove donor TM that were elicited by prior
exposure through pregnancy or blood transfusion to minor H
antigens that may be shared by the transplant recipient or
that are pathogen-speciﬁc but cross-reactive with an allo-
antigen expressed by the recipient. Some studies in murine
models of GVHD have shown that TCM can contribute to
GVHD, although the severity and lethality of GVHD is
consistently higher in mice that receive TN than either TM
subset [34,37]. Whether the GVHD in these models repre-
sents cross reactivity or differences in the composition of the
TCM pool in young laboratory mice with limited pathogen
exposure is uncertain. Limiting dilution assays have
demonstrated that cross-reactive recognition of minor Hantigens by human TM is extremely infrequent [38]. Recog-
nition of disparate MHC molecules by TM is more frequent
[57-59], suggesting this approach may have less merit in the
MHC-mismatched allogeneic HCT setting than alternative
approaches that speciﬁcally remove T cells activated by
allogeneic stimulation. Thus, the logical clinical setting to
ﬁrst test TN depletion would be in HLA-identical allogeneic
HCT where the donor is nonparous and has not had prior
blood transfusions. A clinical trial of this approach is in
progress at our institutions.
The complexity of cell processing for CD45RA depletion is
substantially less than alternative forms of selective deple-
tion of alloreactive T cells that are being investigated in other
clinical trials, such as in vitro stimulation of T cells in PBSC
products followed 2 to 5 days later by depletion of activated
alloreactive T cells using immunomagnetic beads, immuno-
toxins, ﬂuorescent activated cell sorting, or photodynamic
purging [60]. The cell selection procedure we describe is
viewed by the Food and Drug Administration as involving
“minimal manipulation,” can be completed in 8 hours in a
clinical hematopoietic stem cell processing laboratory, and
does not require good manufacturing practice conditions.
Therefore, if CD45RA depletion proves to be successful in
reducing GVHD and providing adequate immune reconsti-
tution in clinical trials, the wider HCT community could
readily adopt this technology. The cost of the 2-stage cell
selection procedure, including reagents and labor, is less than
$20,000. Although the upfront cost is substantial, if CD45RA
depletion is effective in preventing serious or chronic GVHD
and opportunistic infections, it is likely to be cost effective
when one considers the cost of post-HCT care for GVHD
(procedures, medications, hospitalizations) and severe
opportunistic infections (medications, hospitalization,
intensive care unit costs). Furthermore, the cost of CD45RA
depletion compares favorably with alternative new forms of
in vitroTcell depletion, such as the depletion of ab Tcells and
B cells from PBSC.
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